The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines

The novel mechanism of lenalidomide activity

(2015) E. C. Fink et al.   BLOOD

The role of MAPK signalling pathways in the response to endoplasmic reticulum stress

(2014) Nicola J. Darling et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines

(2014) Maria Cosenza et al.   HEMATOLOGICAL ONCOLOGY

Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism

(2014) Kwai Fung Hui et al.   INTERNATIONAL JOURNAL OF CANCER

 c-Signaling Cytokines Induce a Regulatory T Cell Phenotype in Malignant CD4+ T Lymphocytes

(2014) M. Kasprzycka et al.   JOURNAL OF IMMUNOLOGY

ER stress-induced cell death mechanisms

(2013) Renata Sano et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sezary syndrome

(2013) C. Querfeld et al.   BLOOD

Protein kinase RNA- like endoplasmic reticulum kinase (PERK) signaling pathway plays a major role in reactive oxygen species (ROS)- mediated endoplasmic reticulum stress- induced apoptosis in diabetic cardiomyopathy

(2013) Zhong-Wei Liu et al.   Cardiovascular Diabetology

A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial

(2013) Franck Morschhauser et al.   EUROPEAN JOURNAL OF CANCER

Lenalidomide in lymphomas and chronic lymphocytic leukemia

(2013) Peter H Wiernik   EXPERT OPINION ON PHARMACOTHERAPY

Modulation of the Akt Pathway Reveals a Novel Link with PERK/eIF2α, which Is Relevant during Hypoxia

(2013) Matías Blaustein et al.   PLoS One

An Involvement of Oxidative Stress in Endoplasmic Reticulum Stress and Its Associated Diseases

(2012) Bidur Bhandary et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers

(2012) Dinis Pedro Calado et al.   NATURE IMMUNOLOGY

A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax®)

(2012) Simon J Harrison et al.   Epigenomics

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

(2011) E. Campo et al.   BLOOD

HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications

(2011) Omar Khan et al.   IMMUNOLOGY AND CELL BIOLOGY

Malignant Cutaneous T-Cell Lymphoma Cells Express IL-17 Utilizing the Jak3/Stat3 Signaling Pathway

(2011) Thorbjørn Krejsgaard et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Akt Determines Cell Fate Through Inhibition of the PERK-eIF2  Phosphorylation Pathway

(2011) Z. Mounir et al.   Science Signaling

Pathological roles of MAPK signaling pathways in human diseases

(2010) Eun Kyung Kim et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Lenalidomide mode of action: linking bench and clinical findings

(2010) Faith Davies et al.   BLOOD REVIEWS

Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma

(2010) Greg Dueck et al.   CANCER

Targeting histone deacetyalses in the treatment of B- and T-cell malignancies

(2010) Jasmine Zain et al.   INVESTIGATIONAL NEW DRUGS

Epigenetics in cancer

(2009) S. Sharma et al.   CARCINOGENESIS

Population Pharmacokinetics of Romidepsin in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma

(2009) S. Woo et al.   CLINICAL CANCER RESEARCH

Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma

(2009) Ulrike Heider et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Histone Deacetylase Inhibitors in Cancer Therapy

(2009) Andrew A. Lane et al.   JOURNAL OF CLINICAL ONCOLOGY

Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?

(2008) L Nolan et al.   BRITISH JOURNAL OF CANCER

Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

(2008) Peter H. Wiernik et al.   JOURNAL OF CLINICAL ONCOLOGY

Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy

(2008) Kathryn F. Tonissen et al.   MOLECULAR NUTRITION & FOOD RESEARCH